This page is being revised. For current information on the use of bebtelovimab, see the Panel’s recent statement.
Anti-SARS-CoV-2 Monoclonal Antibodies
Last Updated: August 18, 2022
The SARS-CoV-2 genome encodes 4 major structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), as well as nonstructural and accessory proteins. The spike protein is further divided into 2 subunits, S1 and S2, that mediate host cell attachment and invasion. Through its receptor-binding domain (RBD), S1 attaches to angiotensin-converting enzyme 2 (ACE2) on the host cell; this initiates a conformational change in S2 that results in virus-host cell membrane fusion and viral entry.1 Anti-SARS-CoV-2 monoclonal antibodies (mAbs) that target the spike protein have been shown to have clinical benefits in treating SARS-CoV-2 infection. The anticipated activity of the different anti-SARS-CoV-2 mAb therapies varies dramatically depending on the circulating variant. The recommendations and discussion below pertain only to anti-SARS-CoV-2 mAb products for the treatment of COVID-19. Currently, no product is available for post-exposure prophylaxis (PEP). For recommendations and discussion regarding the use of tixagevimab plus cilgavimab (Evusheld) as pre-exposure prophylaxis (PrEP), see Prevention of SARS-CoV-2 Infection.
The Omicron variant of concern (VOC) has become the dominant SARS-CoV-2 variant in the United States.2 This variant and its subvariants have markedly reduced in vitro susceptibility to several anti-SARS-CoV-2 mAbs, especially bamlanivimab plus etesevimab and casirivimab plus imdevimab. Sotrovimab is active against the Omicron BA.1 and BA.1.1 subvariants, but it has substantially decreased in vitro neutralization activity against the Omicron BA.2, BA.4, and BA.5 subvariants. Bebtelovimab retains in vitro neutralization activity against circulating Omicron subvariants.3-5
The COVID-19 Treatment Guidelines Panel’s (the Panel) recommendations for the use of anti-SARS-CoV-2 mAbs are based on current knowledge of the in vitro activities of the available products against the circulating SARS-CoV-2 variants and subvariants.
- For nonhospitalized adults aged ≥18 years with mild to moderate COVID-19 who are at high risk of progressing to severe disease, the Panel recommends using bebtelovimab 175 mg intravenous (IV) injection as an alternative therapy ONLY when both ritonavir-boosted nirmatrelvir (Paxlovid) and remdesivir are not available, feasible to use, or clinically appropriate (CIII).
- Treatment should be initiated as soon as possible and within 7 days of symptom onset.
- See the Centers for Disease Control and Prevention (CDC) webpage People With Certain Medical Conditions for information on medical conditions that are associated with an increased risk of progression to severe COVID-19 and Therapeutic Management of Nonhospitalized Adults With COVID-19 for further guidance on the use of bebtelovimab.
- For recommendations for nonhospitalized children, see Therapeutic Management of Nonhospitalized Children With COVID-19.
- Bebtelovimab is 1 of the treatment options that can be considered for adults aged ≥18 years with mild to moderate COVID-19 who are hospitalized for a reason other than COVID-19 if they otherwise meet the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) criteria for outpatient treatment.
Bamlanivimab Plus Etesevimab, Casirivimab Plus Imdevimab, and Sotrovimab
- Because the Omicron VOC is now the dominant variant in the United States, the Panel recommends against using bamlanivimab plus etesevimab, casirivimab plus imdevimab, or sotrovimab for the treatment of COVID-19 (AIII).
- For information on medical conditions and other factors that are associated with an increased risk of progression to severe COVID-19, see the CDC webpage People With Certain Medical Conditions. The decision to use anti-SARS-CoV-2 mAbs for a patient should be based on an individualized assessment of the risks and benefits.6 Not all of the conditions and factors considered to be high risk were well-represented in the clinical trials that provide support for the mAb EUAs.
- Some rare medical conditions that are not listed on the CDC webpage Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19 and other factors (e.g., race, ethnicity) may be associated with a high risk of progressing to severe COVID-19. It is important to note that the likelihood of developing severe COVID-19 increases when a person has multiple high-risk conditions or comorbidities.7-10
- Previously published clinical trials that evaluated the use of anti-SARS-CoV-2 mAbs for the treatment of COVID-19 largely enrolled an unvaccinated participant population. The risk of progression to severe COVID-19 in high-risk patients is substantially greater for those who are not vaccinated against COVID-19 and those who are vaccinated but do not mount an adequate immune response to the vaccine due to an underlying immunocompromising condition.
- If indicated, treatment with anti-SARS-CoV-2 mAbs should be started as soon as possible after SARS-CoV-2 infection is confirmed by an antigen test or a nucleic acid amplification test and within 7 days of symptom onset.
- Anti-SARS-CoV-2 mAbs should be administered in a setting where severe hypersensitivity reactions, such as anaphylaxis, can be managed. Patients should be monitored for at least 1 hour after the injection.
- See Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment COVID-19 in Nonhospitalized Patients When There Are Logistical Constraints for the Panel’s recommendations in situations where therapies for the treatment of mild to moderate COVID-19, including anti-SARS-CoV-2 mAbs, cannot be offered to all eligible patients.
- Data are limited on the combined use of antiviral agents and anti-SARS-CoV-2 mAbs for the treatment of nonhospitalized patients with COVID-19. Clinical trials are needed to determine whether this combination therapy has a role in the treatment of COVID-19.
- Patients who are severely immunocompromised may have prolonged SARS-CoV-2 replication, leading to more rapid viral evolution. There is a concern that using a single anti-SARS-CoV-2 mAb in these patients may result in the emergence of resistant virus. Additional studies are needed to assess this risk.11,12
Anti-SARS-CoV-2 Monoclonal Antibodies That Have Received Emergency Use Authorizations
Five anti-SARS-CoV-2 mAb products have received EUAs from the FDA. The authorized anti-SARS-CoV-2 mAb products that are currently available for use are:
- Bebtelovimab: This recombinant neutralizing human mAb binds to the spike protein of SARS-CoV-2. Bebtelovimab retains in vitro neutralization activity against all circulating Omicron subvariants, but there are no clinical efficacy data on the treatment of patients who are at high risk of progressing to severe COVID-19.3-5,13-15
- Tixagevimab plus cilgavimab: These recombinant human anti-SARS-CoV-2 mAbs bind to nonoverlapping epitopes of the spike protein RBD of SARS-CoV-2. Tixagevimab plus cilgavimab has retained in vitro neutralization activity against the Omicron BA.2 subvariant.16-19 Tixagevimab plus cilgavimab has modestly reduced in vitro neutralization activity against the Omicron BA.4 and BA.5 subvariants, but this combination is expected to be clinically active. Tixagevimab plus cilgavimab is authorized for use as PrEP in certain patients and should be given in repeat doses every 6 months if ongoing protection is needed. See Prevention of SARS-CoV-2 Infection for more information.
The distribution of the following authorized anti-SARS-CoV-2 mAb products has paused in the United States. The Omicron VOC has markedly reduced in vitro susceptibility to these products; therefore, they are not expected to provide a clinical benefit for patients with COVID-19 caused by the Omicron VOC:20,21
- Bamlanivimab plus etesevimab: These neutralizing mAbs bind to different, but overlapping, epitopes of the spike protein RBD of SARS-CoV-2.
- Casirivimab plus imdevimab: These recombinant human mAbs bind to nonoverlapping epitopes of the spike protein RBD of SARS-CoV-2.
- Sotrovimab: This mAb was originally identified in 2003 from a survivor of SARS-CoV infection. It targets an epitope of the RBD of the spike protein that is conserved between SARS-CoV and SARS-CoV-2.
- Sotrovimab retains in vitro neutralization activity against the Omicron BA.1 and BA.1.1 subvariants, but it has substantially decreased in vitro neutralization activity against the Omicron BA.2, BA.4, and BA.5 subvariants and is not expected to provide a clinical benefit at this time.5,6,14,22
SARS-CoV-2 Variant Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
In laboratory studies, some SARS-CoV-2 variants that harbor certain mutations have markedly reduced susceptibility to several of the authorized anti-SARS-CoV-2 mAbs.23 The clinical relevance of the reduced in vitro susceptibility of select variants to anti-SARS-CoV-2 mAbs is under investigation.
Population-based genomic surveillance of the types and proportions of circulating SARS-CoV-2 variants and studies on the susceptibility of different variants to the available anti-SARS-CoV-2 mAbs will be important in defining the utility of specific anti-SARS-CoV-2 mAbs in the future. See the CDC COVID Data Tracker for regular updates on the data for SARS-CoV-2 variants.
Table A. SARS-CoV-2 Variants and Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
In placebo-controlled, randomized trials in nonhospitalized patients with mild to moderate COVID-19 symptoms and certain risk factors for disease progression, the use of anti-SARS-CoV-2 mAb products reduced the risk of hospitalization and death (see Table 4b).6,13,24,25 These studies were conducted before the widespread circulation of the Omicron VOC.
Based on in vitro data, bebtelovimab is expected to have activity against a broad range of SARS-CoV-2 variants, including the Omicron VOC and its BA.1, BA.2, BA.4, and BA.5 subvariants.13-15 The Panel’s recommendation for bebtelovimab is primarily based on laboratory data showing its potent activity against the Omicron VOC (including the BA.1 and BA.2 subvariants) and other VOCs, as well as on limited clinical trial data from the Phase 2 BLAZE-4 study.13
In treatment arms 9 to 11 in the Phase 2 BLAZE-4 trial, patients with COVID-19 who were at low risk of disease progression were randomized to receive a single infusion of bamlanivimab plus etesevimab plus bebtelovimab (n = 127), bebtelovimab alone (n = 125), or placebo (n = 128).13 Among these individuals, the mean decline in viral load at Day 5 was greater in the 2 bebtelovimab arms than in the placebo arm. The median time to sustained symptom resolution was 6 days in the bebtelovimab alone arm and 8 days in the placebo arm (P = 0.003).
Large randomized controlled trials are needed to fully evaluate the efficacy of bebtelovimab in a high-risk population. Nevertheless, when other therapeutic options are not available, feasible to use, or clinically appropriate, in vitro susceptibility data and the antiviral activity and clinical benefits observed in Phase 2 trials support the use of bebtelovimab for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe COVID-19. In addition, bebtelovimab has mechanisms of action that are similar to those of other authorized anti-SARS-CoV-2 mAbs that have shown definitive clinical benefits in this population.
Bamlanivimab Plus Etesevimab
The distribution of bamlanivimab plus etesevimab has paused in the United States because the Omicron VOC and its subvariants have markedly reduced in vitro susceptibility to this mAb regimen.20 Prior to the spread of the Omicron VOC, the Phase 3 BLAZE-1 trial had demonstrated a clinical benefit of bamlanivimab plus etesevimab in people with mild to moderate COVID-19 who were at high risk of progressing to severe disease or hospitalization.26
Casirivimab Plus Imdevimab
The distribution of casirivimab plus imdevimab has paused in the United States because the Omicron VOC and its subvariants have markedly reduced in vitro susceptibility to this mAb regimen.21 Prior to the spread of the Omicron VOC, the FDA had authorized the use of casirivimab plus imdevimab for the treatment of people with mild to moderate COVID-19 who are at high risk of progressing to severe disease or hospitalization.6
Sotrovimab retains in vitro neutralization activity against the BA.1 and BA.1.1 subvariants of the Omicron VOC, but it has substantially decreased in vitro neutralization activity against the Omicron BA.2, BA.4, and BA.5 subvariants. It is not expected to provide a clinical benefit to patients infected with these subvariants.6 Because the Omicron BA.5 subvariant is now the dominant circulating subvariant in all regions of the United States, distribution of sotrovimab has paused, and the Panel no longer recommends using sotrovimab to treat COVID-19.
See Table 4b for more information on the clinical trials evaluating the safety and efficacy of anti-SARS-CoV-2 mAbs in patients with COVID-19.
Using Anti-SARS-CoV-2 Monoclonal Antibodies in Patients Hospitalized for COVID-19
The anti-SARS-CoV-2 mAbs available through FDA EUAs are not authorized for the treatment of COVID-19 in the following patients:
- Those hospitalized for COVID-19
- Those who require oxygen therapy or respiratory support due to COVID-19
- Those who are on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity and who require an increase in oxygen flow rate from baseline or respiratory support because of COVID-19
The FDA EUAs permit the use of anti-SARS-CoV-2 mAb products in patients who are hospitalized for a diagnosis other than COVID-19, provided they have mild to moderate COVID-19 and are at high risk of progressing to severe disease.13,25,27,28
Anti-SARS-CoV-2 mAbs have been evaluated in hospitalized patients with severe COVID-19. In general, anti-SARS-CoV-2 mAbs were not found to provide a clinical benefit in hospitalized patients, although some subanalyses have reported potential benefits.29-32 In the RECOVERY trial, casirivimab plus imdevimab demonstrated a potential benefit in individuals who were seronegative for the SARS-CoV-2 anti-spike protein antibody. Patients who received casirivimab 4 g plus imdevimab 4 g had a significant reduction in 28-day all-cause mortality (396 of 1,633 patients [24%]) compared with patients who received usual care (452 of 1,520 patients [30%]; rate ratio 0.79; 95% CI, 0.69–0.91; P = 0.0009).33 A second trial in hospitalized patients with COVID-19 also reported a reduction in mortality among seronegative patients who received casirivimab plus imdevimab.34,35
The current EUA does not authorize the use of the higher dose of casirivimab plus imdevimab that was evaluated in these trials. This anti-SARS-CoV-2 mAb combination is also not expected to be efficacious against the Omicron VOC. In addition, rapid serology testing that can identify seronegative individuals in real time is not widely available.
In the ACTIV-3/TICO trial, the use of tixagevimab plus cilgavimab in hospitalized patients with COVID-19 did not improve the proportion of patients who achieved sustained clinical recovery (which was defined as 14 consecutive days at home after hospital discharge). However, the relative risk of mortality decreased by approximately 30% among patients who received this combination.32 Tixagevimab plus cilgavimab is not currently authorized by the FDA for the treatment of patients hospitalized for COVID-19.
Anti-SARS-CoV-2 mAbs may be available through expanded access programs for the treatment of patients who are immunocompromised and are hospitalized because of COVID-19. It is not yet known whether these mAb products provide clinical benefits in people with B-cell immunodeficiency or other immunodeficiencies.
Bebtelovimab should be administered by IV injection and should only be administered in health care settings by qualified health care providers who have immediate access to emergency medical services and medications that treat severe infusion-related reactions. Patients should be monitored for at least 1 hour after the injection.
Hypersensitivity, including anaphylaxis and infusion-related reactions, has been reported in patients who received anti-SARS-CoV-2 mAbs. Rash, diarrhea, nausea, vomiting, dizziness, and pruritus have also been reported.6,13,25,28
Drug-drug interactions are unlikely between the authorized anti-SARS-CoV-2 mAbs and medications that are renally excreted or that are cytochrome P450 substrates, inhibitors, or inducers (see Table 4e).
Considerations in Pregnancy
The use of anti-SARS-CoV-2 mAbs can be considered for pregnant people with COVID-19, especially those who have additional risk factors for severe disease.
As immunoglobulin (Ig) G mAbs, the authorized anti-SARS-CoV-2 mAbs would be expected to cross the placenta. There are no pregnancy-specific data on the use of these mAbs; however, other IgG products have been safely used in pregnant people when indicated. Therefore, authorized anti-SARS-CoV-2 mAbs should not be withheld during pregnancy. When possible, pregnant and lactating people should be included in clinical trials that are evaluating the use of anti-SARS-CoV-2 mAbs for the treatment or prevention of COVID-19.
Considerations in Children
Please see Therapeutic Management of Nonhospitalized Children With COVID-19 for therapeutic recommendations for children with COVID-19.
Bebtelovimab is available for the treatment of COVID-19 and tixagevimab plus cilgavimab is available for SARS-CoV-2 PrEP in all regions of the United States. The broad distribution of bamlanivimab plus etesevimab, casirivimab plus imdevimab, and sotrovimab has paused in the United States because the Omicron VOC has reduced susceptibility to these anti-SARS-CoV-2 mAbs.20,21
- Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41(5):355-359. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32249063.
- Centers for Disease Control and Prevention. COVID data tracker: variant proportions. 2022. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed August 16, 2022.
- Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35714668.
- Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. Nature. 2022;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35790190.
- Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 Omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22(7):942-943. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35690075.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of sotrovimab. 2022. Available at: https://www.fda.gov/media/149534/download.
- Kim L, Garg S, O’Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis. 2021;72(9):e206-e214. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32674114.
- Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32217650.
- Zhang Y, Luo W, Li Q, et al. Risk factors for death among the first 80,543 COVID-19 cases in China: relationships between age, underlying disease, case severity, and region. Clin Infect Dis. 2022;74(4):630-638. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34043784.
- Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a U.S. national sample of patients with COVID-19. JAMA Netw Open. 2020;3(12):e2029058. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33301018.
- Rockett R, Basile K, Maddocks S, et al. Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use. N Engl J Med. 2022;386(15):1477-1479. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35263515.
- Huygens S, Munnink BO, Gharbharan A, Koopmans M, Rijnders B. High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant. medRxiv. 2022;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2022.04.06.22273503v1.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.
- Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604(7906):553-556. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35240676.
- Westendorf K, Zentelis S, Wang L, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39(7):110812. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35568025.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2022. Available at: https://www.fda.gov/media/154701/download.
- Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;602(7898):671-675. Available at: https://pubmed.ncbi.nlm.nih.gov/35016199.
- Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602(7898):664-670. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35016195.
- VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28(3):490-495. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35046573.
- Public Health Emergency. Bamlanivimab/etesevimab. 2022. Available at: https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/default.aspx. Accessed August 16, 2022.
- Public Health Emergency. REGEN-COV. 2022. Available at: https://www.phe.gov/emergency/events/COVID19/investigation-MCM/cas_imd/Pages/default.aspx. Accessed August 16, 2022.
- Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N Engl J Med. 2022;386(15):1475-1477. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35263535.
- Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html. Accessed August 16, 2022.
- Food and Drug Administration. Fact sheet for health care providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. 2022. Available at: https://www.fda.gov/media/145802/download.
- Food and Drug Administration. Fact sheet for health care providers: emergency use authorization (EUA) of REGEN-COV (casirivimab and imdevimab). 2021. Available at: https://www.fda.gov/media/145611/download.
- Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2021;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34718468.
- Food and Drug Administration. Frequently asked questions on the emergency use authorization of bamlanivimab and etesevimab. 2022. Available at: https://www.fda.gov/media/145808/download.
- Food and Drug Administration. Frequently asked questions on the emergency use authorization of sotrovimab. 2022. Available at: https://www.fda.gov/media/149535/download.
- ACTIV-TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. N Engl J Med. 2021;384(10):905-914. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33356051.
- ACTIV-3/TICO Bamlanivimab Study Group. Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial. Ann Intern Med. 2021;175(2):234-243. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34928698.
- ACTIV-3/Therapeutics for Inpatients With COVID-19 Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2022;22(5):622-635. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34953520.
- ACTIV-3-Therapeutics for Inpatients With COVID-19 Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35817072.
- RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10325):665-676. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35151397.
- Somersan-Karakaya S, Mylonakis E, Menon VP, et al. Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19. J Infect Dis. 2022;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35895508.
- Mylonakis E, Somersan-Karakaya S, Sivapalasingam S, et al. LB4. Casirivimab and imdevimab for treatment of hospitalized patients with COVID-19 receiving low flow or no supplemental oxygen. Open Forum Infect Dis. 2021;8:S809–S810. Available at: https://academic.oup.com/ofid/article/8/Supplement_1/S809/6450934.